Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT) is a phase 2, interventional study registered as NCT07026422 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 54 participants, started 2025-04-30 and due to reach its primary completion in 2026-11-30. Interventions recorded: Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy. Conditions listed: Rectal Malignant Neoplasms. Primary outcome: Overall complete response (CR) rate. Colorectal eligibility wording from the registry: "Histologically confirmed pMMR/MSS rectal adenocarcinoma, defined by MRI as clinical stage II (T3-4, N-) or stage III (any T, N+)". Sites: China. No results are recorded here; the registry entry is the source.